Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Lawsuit Against ESSA Pharma Inc.

New York, NY / ACCESS Newswire / February 14, 2025 /

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ESSA Pharma Inc. (“ESSA” or “the Company”) (NASDAQ:EPIX) and certain of its officers.

Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ESSA securities between December 12, 2023 and October 31, 2024, both dates inclusive (the “Class Period”).

The allegations in the lawsuit suggest that there have been violations of federal securities laws by ESSA Pharma Inc. and certain officers during the specified Class Period. Investors who purchased or acquired ESSA securities during this time frame may be entitled to recover damages through this class action lawsuit.

Investors should pay close attention to the developments of this case and consult with legal counsel to determine their rights and the best course of action. It is important for investors to understand the implications of securities law violations and take appropriate steps to protect their investments.

As this class action lawsuit progresses, it will be crucial for investors to stay informed and actively participate in the legal proceedings to ensure that their rights are upheld and any potential damages are recovered.

How This Will Affect Me:

As an investor who purchased or acquired ESSA Pharma Inc. securities between December 12, 2023 and October 31, 2024, you may be eligible to participate in the class action lawsuit and seek damages for any alleged violations of federal securities laws. It is important to stay informed about the developments of the case and consult with legal counsel to understand your rights and options.

How This Will Affect the World:

The outcome of this class action lawsuit against ESSA Pharma Inc. could have broader implications for the financial markets and investors. If the allegations of securities law violations are proven, it may lead to increased scrutiny of corporate governance practices and accountability among publicly traded companies. This case could serve as a reminder of the importance of transparency and adherence to securities regulations in the investment community.

Conclusion:

In conclusion, the class action lawsuit filed against ESSA Pharma Inc. highlights the importance of investor protection and the enforcement of securities laws. Investors should closely monitor the developments of this case and consult with legal counsel to understand their rights and options. It is essential for investors to stay informed and actively participate in legal proceedings to ensure that their interests are safeguarded.